4 ASX shares Macquarie says could return more than 40%

The broker has made some bold predictions.

When it comes to stock picking it can pay to listen to the experts.

I've had a look through the research reports issued by Macquarie over the past week and filtered out a handful which the analyst team thinks will outperform over the next year.

Let's see who they like.

A woman in a red dress holding up a red graph.

Image source: Getty Images

Megaport Ltd (ASX: MP1)

This company is in the midst of a major capital raise under which it is looking to raise $827 million, including $309 million from existing shareholders.

Despite the raise being conducted at $14.30 per share, Megaport shares have held up well and are currently changing hands for $18.88.

This can be explained by the fact that the company also announced some major contract wins at the same time as it announced the capital raise.

The new contracts were worth about $458.9 million and would require $369.5 million in infrastructure spending, "primarily for high-performance NVIDIA GPUs, network, and storage infrastructure".

Macquarie said Megaport provides AI exposure for investors with shorter lead times and less capital expenditure than data centre operators.

Macquarie has a price target of $27.80 on Megaport shares.

Viva Energy Ltd (ASX: VEA)

This company had a setback with a fire at its Geelong refinery in April, but Macquarie expects that repairs should be nearing completion.

Macquarie says Viva could deliver its best refining half in four years, even taking into account the fire impact.

A new head of the convenience division is also set to start soon, to help drive growth in what has been a "troubled" part of the business.

Macquarie has a $3.40 price target on Viva shares compared to $2.24 currently.

Fineos Corporation Ltd (ASX: FCL)

This company develops software for use by the global health insurance sector and has had recent contract wins in Australia and overseas.

The company recently reaffirmed revenue guidance in the range of €147m to €152m, and its closing cash balance at the end of March was €47.1m, up by €11.7m over the quarter.

Macquarie said the company was trading at a discount to one of its peers, GWRE, and its "medium-term revenue mix targets imply an acceleration in revenue vs Macquarie forecasts''.

Macquarie has a price target of $3.50 on Fineos shares compared to $2.15 currently.

 Ebos Group Ltd (ASX: EBO)

Ebos Group shares are down almost 50% over the past 12 months; however, the Macquarie team believes the company is well-placed for share price gains.

The company is also paying a dividend yield of 5.9% this year, with that figure expected to increase to 6.9% in 2028.

EBOS in April downgraded its FY26 underlying EBITDA guidance to $610 to $620 million, down from a previous range of $615 to $635 million, due to higher fuel and energy costs.

Macquarie said on the positive side of the ledger, a new First Pharmaceutical Wholesaler Agreement has been struck with the Federal Government, which will benefit EBOS' Symbion division.

Macquarie has a price target of NZ$36.44 on the stock compared with NZ$20.66 at the time of writing.

Motley Fool contributor Cameron England has positions in Megaport. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended FINEOS Corporation, Macquarie Group, and Megaport. The Motley Fool Australia has positions in and has recommended FINEOS Corporation. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Buy, hold, sell: Domino's Pizza, Super Retail, PLS shares

Let's check out some new ratings on ASX shares today.

Read more »